StrokeAlarm Trial 2

NCT ID: NCT05144932

Last Updated: 2024-03-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2025-12-31

Brief Summary

This open, multicenter, prospective, singel-arm study will evaluate usability and feasibility of a wearable stroke indication system (Stroke Alarm) in patients with recent TIA, recent minor stroke without persistent arm motor deficit, or atrial fibrillation up to 1 month.

Detailed Description

The aim of this study is to test the safety and feasibility of the CE-marked wearable system for early stroke indication to indicate the onset of stroke in real life.

Our hypothesis is that the device is well tolerated with an acceptable number of adverse events such as direct complications of the bracelets or unbearable amounts of false alarms or false alarms during sleep.

The device can be used to monitor arm motor function for long time. The ability to detect arm paresis (indicating the onset of a stroke) will be studied as well, but the trial is single-armed and not designed to assess neither the efficacy of stroke indication nor shortened patient-delay.

Anticipated adverse device effects that are to be assessed.

• Participants being unable to operate the device.
• Frequency of alarms specified for the different alarm escalation steps.
• User compliance.
• User experience.
• Alarm recipient experience
• Barriers for use will be identified (for example advanced age or other patients' characteristics)

This is a prospective trial without a comparator group (single arm). All patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) or TIA or newly diagnosed atrial fibrillation/flutter at the participating hospitals are screened daily (Monday - Friday) for eligibility by dedicated research nurses, mainly through the electronic patient chart (Melior). Atrial fibrillation patients may also be identtifyed using the Auricula registry for oral anticoagulation. When in doubt about the diagnosis or eligibility for other reasons research nurses consult either the physician responsible for the patient or the PI.

All patients screened are documented, including reasons for non-inclusion and exclusion. The screening log is kept in the Investigators site file (ISF) that are located in locked research offices at the participating hospitals. Source data such as inclusion forms are stored in the same research offices, within locked cabinets.

All included patients are contacted by a research nurse at one month from inclusion (plus maximum 14 days) for a planned follow-up phone call.

The follow-up appointments are scheduled by phone/letter, but prior to the visit, a notice will be sent, and the patient is encouraged to complete the questionnaire before the visit and is also informed that it is possible to complete the questionnaire during the follow-up. Interpreter-assistance or use of questionnaires translated to foreign languages is allowed during the follow-up visit.

The follow-up is estimated to take one hour. Prior to the follow-up the electronic journal is checked for any admissions for stroke or TIA during the follow-up period and in such case any arm motor involvement and the time from onset to arrival to hospital is also registered.

At the follow-up, a structured reporting form is used (StrokeAlarm Pro CRF). Baseline data for all patients are registered in the CRF at inclusion and/or at follow-up.

The research nurse fills in the CRF at inclusion and follow-up and enters the data into SPSS. The PI validates the CRF items in SPSS using cross control and frequencies analysis of number of answers.

Data from the device backend server is extracted by a predefined format (Structured Backend Data Report StrokeAlarm Pro DRF) into the SPSS data file.

Analyses are made on pseudoanonymized data (personal identification number replaced by serial number). A key will be kept in a locked research room at the hospital throughout the course of the study and the analytic phase.

SPSS will be used for all statistical analyses. Data will be summarized and presented with descriptive statistics and graphs, as well as linear models.

The patients are in this clinical trial instructed to use the device continuously for 1 month.

No comparator will be used in this clinical trial. The main reason is that there are no similar systems available. Feasibility is the main research question.

Each patient that are participating in this clinical trial will receive one pair of devices.

The devices are paired and designed for continuous use for up to 6 months. For hygienic reasons the devices will not be re-used for other subjects. The devices will be collected by the manufacturer at the end of the study.

9.2.1 Other medical device or medication to be used during the clinical investigation.

Simultaneous inclusion in other studies that require bracelets are not permitted since this may negatively impact the user experience. Simultaneous inclusion in other ongoing studies on for example drugs, is permitted.

Conditions

Stroke; Atrial Fibrillation; TIA

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

StrokeAlarm use

This is a single arm study. All participants will be instructed to use the StrokeAlarm medical device for 1 month.

Group Type: EXPERIMENTAL

Stroke Alarm

Intervention Type: DEVICE

The patients are in this clinical trial instructed to use the device continuously for 1 month.

Interventions

Stroke Alarm

The patients are in this clinical trial instructed to use the device continuously for 1 month.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age 18 years or older

2. Patients with 2A. Diagnosed (ICD-10) TIA (G45.9: Transitory ischemic attack or G45.3: Amaurosis fugax, or 2B. ICD-10 ischemic stroke, I63.0-9. 2C. Newly diagnosed atrial fibrillation. 2D. Atrial fibrillation with an increased risk of stroke (contraindication to oral anticoagulants, reduced dose of oral anticoagulants or other risk factors presenting an estimated annual stroke risk of 5% or more despite anticoagulants treatment.

3. Subject has after study specific information consent to participation by signing the Ethics committee-approved inform consent form.

Exclusion Criteria

1. Already included in the study in connection with previous TIA/stroke.

2. Has an affected arm function due to previous stroke or other illness/trauma.

3. Cannot provide informed consent to participation in the study.

4. Does not speak Swedish or English in speech and writing.

5. Assessed due to other diseases or circumstances in general cannot contribute to planned follow-up within the framework of the study.

6. Do not want to participate.

7. During the study period, do not have access to a compatible smartPhone.

8. Not deemed capable of managing the Stroke Alarm smartphone app.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Region Skane

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Magnus Esbjörnsson, MD

Role: PRINCIPAL_INVESTIGATOR

Region Skåne

Locations

Hässleholms sjukhus

Hässleholm, , Sweden

Site Status: RECRUITING

Countries

Sweden

Central Contacts

Johan Wasselius, MD, PhD

Role: CONTACT

johan.wasselius@med.lu.se

+4646173082

Åke Holmberg, MSc

Role: CONTACT

ake.holmberg@reegionstockholm.se

Facility Contacts

Magnus Esbjörnsson, MD

Role: primary

magnus.esbjornsson@skane.se

+46451298753

Other Identifiers

CIV-SE-21-08-037407

Identifier Type: -

Identifier Source: org_study_id